

Bruno L Cadilha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/978800/publications.pdf>

Version: 2024-02-01

19
papers

1,681
citations

623734

14
h-index

839539

18
g-index

20
all docs

20
docs citations

20
times ranked

2895
citing authors

#	ARTICLE	IF	CITATIONS
1	Flow cytometry detection and quantification of CAR T cells into solid tumors. <i>Methods in Cell Biology</i> , 2022, 167, 99-122.	1.1	2
2	A modular and controllable T cell therapy platform for acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2243-2257.	7.2	24
3	Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy. , 2021, 9, e000832.		23
4	T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. <i>Nature Biomedical Engineering</i> , 2021, 5, 1246-1260.	22.5	80
5	Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins. <i>Blood Cancer Journal</i> , 2021, 11, 108.	6.2	17
6	Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. <i>Science Advances</i> , 2021, 7, .	10.3	56
7	CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. <i>Cell</i> , 2021, 184, 4512-4530.e22.	28.9	180
8	Challenges in Clinical Trial Design for T Cell-Based Cancer Immunotherapy. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 47-49.	4.7	9
9	Determinants of response and resistance to CAR T cell therapy. <i>Seminars in Cancer Biology</i> , 2020, 65, 80-90.	9.6	59
10	Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 5890-5900.	7.0	31
11	Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis. <i>Science Advances</i> , 2019, 5, eaav4275.	10.3	139
12	Advances in cancer immunotherapy 2019 – latest trends. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 268.	8.6	401
13	Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy. <i>Cells</i> , 2019, 8, 472.	4.1	122
14	Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy. <i>Nature</i> , 2019, 570, 112-116.	27.8	147
15	Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1283.	4.1	296
16	Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma. <i>Translational Oncology</i> , 2019, 12, 350-360.	3.7	27
17	High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy. <i>British Journal of Cancer</i> , 2019, 120, 79-87.	6.4	36
18	PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma. <i>Frontiers in Immunology</i> , 2018, 9, 1955.	4.8	24

#	ARTICLE	IF	CITATIONS
19	Enabling T Cell Recruitment to Tumours as a Strategy for Improving Adoptive T Cell Therapy. European Oncology and Haematology, 2017, 13, 66.	0.0	8